专利检索 ap:("The Johns Hopkins University" OR "Institute of Organic Chemistry AND Biochemistry AS CR v.v.i.") AND inv:"Jan Vavra" 第 1 页

1.

发明申请
MEBENDAZOLE PRODRUGS WITH ENHANCED SOLUBILITY AND ORAL BIOAVAILABILITY 有权

公开(公告)号：US20210205271A1

公开(公告)日：2021-07-08

申请号：US16967924

申请日：2019-02-08

申请人： The Johns Hopkins University , Institute of Organic Chemistry and Biochemistry AS CR v.v.i.

发明人： Barbara Slusher , Rana Rais , Gregory Riggins , Pavel Majer , Tomas Tichy , Jan Vavra , Andrej Jancarik

IPC分类号： A61K31/4184 , A61K45/06 , C07D235/32 , C07H15/26 , C07F9/6506 , A61K31/7056 , A61K31/675 , A61K31/685 , C07D405/12

摘要： Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.

2.

发明申请
NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS 审中-公开

公开(公告)号：US20190352255A1

公开(公告)日：2019-11-21

申请号：US16461630

申请日：2017-11-20

申请人： The Johns Hopkins University , Institute of Organic Chemistry and Biochemistry AS CR v.v.i.

发明人： Barbara Slusher , Rana Rais , Jan Vavra , Tomas Tichy , Pavel Majer , Andrej Jancarik , Lukas Tenora

IPC分类号： C07C259/06 , C07D317/38 , C07C259/08 , A61P25/02

摘要： Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.

3.

发明授权
Prodrug compositions and utility of hydroxamate-based GCPII inhibitors 有权

公开(公告)号：US11059775B2

公开(公告)日：2021-07-13

申请号：US16461630

申请日：2017-11-20

申请人： The Johns Hopkins University , Institute of Organic Chemistry and Biochemistry AS CR v.v.i.

发明人： Barbara Slusher , Rana Rais , Jan Vavra , Tomas Tichy , Pavel Majer , Andrej Jancarik , Lukas Tenora

IPC分类号： C07C259/06 , A61P25/02 , C07C259/08 , C07D317/38

摘要： Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.

4.

发明授权
Prodrugs of hydroxamate-based GCPII inhibitors 有权

公开(公告)号：US11866394B2

公开(公告)日：2024-01-09

申请号：US17372899

申请日：2021-07-12

申请人： The Johns Hopkins University , Institute of Organic Chemistry and Biochemistry AS CR v.v.i.

发明人： Barbara Slusher , Rana Rais , Jan Vavra , Tomas Tichy , Pavel Majer , Andrej Jancarik , Lukas Tenora

IPC分类号： C07C259/06 , A61P25/02 , C07C259/08 , C07D317/38

CPC分类号： C07C259/06 , A61P25/02 , C07C259/08 , C07D317/38

摘要： Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.

5.

发明授权
Mebendazole prodrugs with enhanced solubility and oral bioavailability 有权

公开(公告)号：US11712435B2

公开(公告)日：2023-08-01

申请号：US16967924

申请日：2019-02-08

申请人： The Johns Hopkins University , Institute of Organic Chemistry and Biochemistry AS CR v.v.i.

发明人： Barbara Slusher , Rana Rais , Gregory Riggins , Pavel Majer , Tomas Tichy , Jan Vavra , Andrej Jancarik , Lukas Tenora

IPC分类号： A61K31/4184 , A61K31/685 , A61K31/7056 , C07D235/32 , C07D405/12 , C07F9/6506 , A61P35/00 , C07H13/12 , A61K31/675 , A61K45/06 , C07H15/26

CPC分类号： A61K31/4184 , A61K31/675 , A61K31/685 , A61K31/7056 , A61K45/06 , A61P35/00 , C07D235/32 , C07D405/12 , C07F9/65068 , C07H13/12 , C07H15/26

摘要： Prodrugs of mebendazole and methods for their use in treating a disease, disorder, or disorder, including cancer, are disclosed.

6.

发明申请
PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS 有权

公开(公告)号：US20210355079A1

公开(公告)日：2021-11-18

申请号：US17372899

申请日：2021-07-12

申请人： The Johns Hopkins University , Institute of Organic Chemistry and Biochemistry AS

发明人： Barbara Slusher , Rana Rais , Jan Vavra , Tomas Tichy , Pavel Majer , Andrej Jancarik , Lukas Tenora

IPC分类号： C07C259/06 , A61P25/02 , C07C259/08 , C07D317/38

摘要： Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.